◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Towa Pharmaceutical Co., Ltd. (4553)

Name: Towa Pharmaceutical Co., Ltd.（4553）— 財務諸表の推移
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

Healthcare · ウォール街（米国） · 最終更新: 2026-10-02

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas. It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products. The company also offers IT service related to healthcare; disease risk testing services; and sale of quasi drugs.

主要指標

時価総額: JPY 172 billion
売上高（2026-03-31 期末の会計年度）: JPY 273.7B
当期純利益: JPY 5.2B
売上総利益率: 36.2%
純利益率: 1.9%

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→

年次損益計算書

損益計算書	2026-03-31	2025-03-31	2024-03-31	2023-03-31
売上高合計	JPY 273.7B	JPY 259.6B	JPY 227.9B	JPY 208.9B
売上総利益	JPY 99.1B	JPY 94.7B	JPY 81.4B	JPY 72.7B
営業利益（EBIT）	JPY 23.1B	JPY 23.2B	JPY 17.6B	JPY 5.5B
当期純利益	JPY 5.2B	JPY 19.0B	JPY 16.2B	JPY 2.2B

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は 4553 のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/4553

類似企業

4887 · Sawai Group Holdings Co., Ltd.

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.